REGENXBIO Inc. - SIC # 6710 -

Ticker Exchange SIC # Website Latest Ticker
RGNX Nasdaq 6710 www.regenxbio.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for REGENXBIO Inc.

REGENXBIO Q2 Earnings Call Highlights - Aug 7th, 2026 5:03 am
Regenxbio Inc (RGNX) (Q2 2026) Earnings Call Highlights: Cash Runway Extended into Q4 2027 on ... - Aug 6th, 2026 1:02 pm
Regenxbio (RGNX) Beats Q2 Earnings and Revenue Estimates - Aug 6th, 2026 7:50 am
REGENXBIO Reports Second Quarter 2026 Financial Results and Operational Highlights - Aug 6th, 2026 5:05 am
Niagen Bioscience (NAGE) Meets Q2 Earnings Estimates - Aug 4th, 2026 3:40 pm
REGENXBIO to Host Conference Call on August 6 to Discuss Second Quarter 2026 Financial Results and Operational Highlights - Aug 3rd, 2026 5:05 am
New Strong Sell Stocks for July 23rd - Jul 23rd, 2026 3:45 am
REGENXBIO Presents Positive Long-Term Data for Surabgene Lomparvovec in Wet AMD and Diabetic Retinopathy at American Society of Retina Specialists Annual Meeting - Jul 18th, 2026 12:55 pm
REGENXBIO Announces Pricing of Public Offering of Common Stock and Pre-funded Warrants - Jul 17th, 2026 5:00 am
RGNX Stock Slumps 15% After-Hours — What’s Driving The Selloff? - Jul 16th, 2026 4:36 pm
REGENXBIO Announces Proposed Public Offering of Common Stock - Jul 16th, 2026 2:26 pm
REGENXBIO Announces First Patient Dosed in Phase IIb/III NAAVIGATE Trial of Surabgene Lomparvovec in Diabetic Retinopathy; Company to Receive $100 Million Milestone - Jun 29th, 2026 5:05 am
REGENXBIO Completes Dosing in Confirmatory Study of RGX-202, Marking Completion of Registrational Development Program and Supporting Planned BLA Submission in Q3 2026 - Jun 24th, 2026 5:05 am
Regenxbio Shares Rise on Plans to Resubmit Navsunli BLA for MPS II - Jun 23rd, 2026 8:46 am
FDA changes rare disease tune again as it clears path for Regenxbio’s gene therapy - Jun 23rd, 2026 8:26 am
Sector Update: Healthcare Stocks Rise Late Afternoon - Jun 22nd, 2026 1:43 pm
RGNX Retail Investors See Hope As FDA Reopens Door For Regenxbio’s Hunter Syndrome Therapy - Jun 22nd, 2026 6:44 am
Regenxbio to resubmit gene therapy as FDA backtracks on another drug rejection - Jun 22nd, 2026 5:39 am